EAC REGIONAL PHARMACEUTICAL PLAN OF ACTION 2017-2027

PHARMACONNECT AFRICA CONFERENCE 2019

Glenhove Events Hub, Johannesburg

South Africa

3-5 April 2019

PRESENTATION BY

Mr. AMOS ATUMANYA

INTRODUCTION

- A regional roadmap to guide the East African Community towards evolving an efficient and effective regional pharmaceutical industry that can supply national, regional and international markets with efficacious and quality medicines.

- This plan builds on the first EAC Regional Pharmaceutical Plan of Action (EAC-RPMPOA): 2012-2016 which provided the framework upon which regional and national strategies were aligned in an effort to strengthen the sector.

EAC PARTNER STATES

STRATEGIC INTERVENTIONS

- The strategic interventions focus on supporting the production of advanced formulations for non communicable diseases (delayed release, small volume injectables & bi-layer tablets), APIs & excipients, veterinary medicines as well as harnessing the potential of traditional medicines and natural products

- Specifically, R&D, strategic use of IPRs/benefit sharing and incentives shall be used to attract interest and investment in niche areas.

The plan sets four high-level targets for the development of the EAC pharmaceutical sector:

1. Decrease dependency on pharmaceutical imports from outside EAC from more than 70% to less than 50%.

2. Support the expansion of product portfolio of EAC firms to cater for more than 90% of disease conditions.

3. At least 50% of purchases by EAC national medicines procurement agencies to be sourced from EAC pharmaceutical manufacturers.

4. At least five (5) companies to produce more advanced pharmaceutical formulations such as delayed release formulations, small volume injectables, double layered tablets, among others.

STRATEGIC ACTIVITIES

1. Putting in place a regional GMP roadmap for local manufacturers to upgrade and attain internationally recognised quality standards.
2. Developing a platform for sustainable access to pharmaceutical market intelligence data.
3. Introducing and implementing incentive packages and appropriate financing schemes for local pharmaceutical manufacturers.
4. Promoting policy coherence across sectors at national and regional levels .

5. Establishing a regional framework for mutual recognition of harmonised medicines registration and GMP inspections.

6. Developing and implementing a regional strategy for promoting availability of appropriate skills mix for the local pharmaceutical manufacturing industry.

7. Domesticating public health-related WTO TRIPS flexibilities within the national laws of the Partner States.

8. Putting in place incentive schemes to promote R&D in the pharmaceutical industry.

THANK YOU